Description

ARA-290 Technical Overview

ARA-290, also known as Cibinetide, PHBSP, or Pyroglutamate Helix B Surface Peptide, is a synthetic 11-amino-acid peptide developed from a structural region of erythropoietin (EPO).

Erythropoietin is a naturally occurring glycoprotein hormone primarily involved in red blood cell production. Scientific investigations have also explored EPO-associated signaling pathways involved in cellular responses to injury and inflammation.

ARA-290 was designed to investigate tissue-protective signaling without reproducing the erythropoietic activity associated with conventional erythropoietin receptor activation.

The peptide has been studied in relation to the innate repair receptor (IRR), a proposed receptor complex involving the erythropoietin receptor (EPOR) and beta-common receptor (CD131).

Experimental research has examined this signaling pathway in models of inflammatory injury, cellular stress, and peripheral nerve dysfunction. The precise molecular mechanisms and receptor composition remain under investigation.

ARA-290 consists of 11 amino acid residues and contains an N-terminal pyroglutamate modification.

Published studies have investigated its activity in experimental and clinical research involving inflammatory signaling, peripheral nerve function, and tissue-protective responses.

Compound Information

Chemical Data: PubChem — Cibinetide (CID 91810664)

The molecular formula and molecular weight refer to the parent Cibinetide peptide. Salt preparations, including acetate and trifluoroacetate forms, may have different molecular compositions and weights. PubChem

Storage and Handling

• Store ARA-290 according to the manufacturer’s recommended temperature and stability conditions.
• Keep the container tightly sealed and protected from moisture and direct light.
• Minimize unnecessary temperature fluctuations during laboratory storage.
• Avoid repeated freeze-thaw cycles when handling prepared research solutions.
• Follow established laboratory procedures to maintain compound integrity and minimize contamination.

Lyophilized Format

ARA-290 is commonly supplied for laboratory research in lyophilized (freeze-dried) form.

Lyophilization removes water from peptide preparations and can help maintain compound stability during storage under appropriate conditions.

The stability of lyophilized ARA-290 depends on its formulation, packaging, moisture exposure, and storage environment.

Researchers should refer to batch-specific technical documentation to determine appropriate storage conditions.

Research Use Disclaimer

ARA-290 is supplied exclusively for laboratory research purposes.

This compound is not intended for human or veterinary consumption, clinical use, diagnostic applications, or therapeutic administration.

ARA-290 is not an FDA-approved drug or dietary supplement.

Peptide Lives supplies ARA-290 solely for legitimate scientific research.

ARA-290 RESEARCH

ARA-290 was developed as a synthetic peptide designed to reproduce selected tissue-protective signaling properties associated with erythropoietin without reproducing its principal red blood cell-stimulating activity.

Research into erythropoietin signaling identified potential differences between pathways regulating erythropoiesis and those associated with cellular responses to injury.

These observations contributed to the development of short peptide derivatives, including ARA-290, for investigating tissue-protective signaling mechanisms.

Experimental studies have examined ARA-290 in models of inflammatory injury, peripheral nerve dysfunction, and tissue stress.

Small clinical studies have also investigated Cibinetide in individuals with sarcoidosis-associated small fiber neuropathy.

These investigations have produced preliminary findings involving neuropathic symptom scores, peripheral nerve measurements, and inflammatory signaling.

However, these results do not establish ARA-290 as an approved or proven treatment for neuropathy or other medical conditions.

Innate Repair Receptor Research

ARA-290 is studied for its interaction with the innate repair receptor, a proposed signaling system associated with cellular responses to injury and inflammation.

The receptor has been described in scientific literature as involving the erythropoietin receptor and the beta-common receptor (CD131).

Experimental investigations have examined the relationship between this receptor model and downstream signaling associated with cellular survival and inflammatory regulation.

The precise composition and signaling mechanisms of the tissue-protective receptor remain subjects of scientific investigation.

Tissue-Protective Signaling Research

ARA-290 has been investigated in experimental models examining cellular responses to tissue damage.

Research has focused on pathways associated with cellular stress, inflammatory signaling, and tissue-protective responses.

These investigations aim to characterize how erythropoietin-derived peptides interact with signaling systems involved in tissue injury.

The findings are primarily mechanistic and experimental and should not be interpreted as evidence of established therapeutic efficacy.

Peripheral Nerve Research

One of the most extensively investigated areas of ARA-290 research involves peripheral nerve function.

Clinical studies have examined Cibinetide in individuals experiencing small fiber neuropathy associated with sarcoidosis.

A randomized, double-blind pilot study published in 2012 evaluated ARA-290 in 22 participants.

Investigators reported improvements in selected neuropathy-related symptom measurements compared with placebo.

Other outcomes did not demonstrate significant differences between treatment groups.

These findings supported further investigation but did not establish definitive clinical effectiveness.

Small Fiber Neuropathy Research

Small fiber neuropathy involves damage or dysfunction of small peripheral nerve fibers responsible for sensory and autonomic functions.

ARA-290 has been investigated in studies assessing neuropathic symptoms and structural measurements of peripheral nerve fibers.

A 2013 randomized clinical investigation examined changes in neuropathy-related symptoms and corneal small nerve fiber density.

Researchers reported improvements in selected symptom measurements and increases in corneal nerve fiber density.

Subsequent clinical investigations further examined corneal nerve fiber measurements and other neurological outcomes.

These studies provide preliminary evidence supporting scientific interest in ARA-290-associated nerve signaling and repair processes, although larger confirmatory studies are necessary.

Inflammatory Signaling Research

ARA-290 has been investigated in experimental research involving inflammatory pathways.

Scientific studies have examined whether activation of tissue-protective signaling systems influences cellular responses associated with inflammation.

These investigations include research into the interaction between erythropoietin-derived peptides, inflammatory signaling molecules, and cellular stress pathways.

Results from experimental models contribute to understanding potential relationships between innate repair signaling and inflammatory regulation.

Cellular Repair Research

ARA-290 is studied in research examining cellular responses following injury and metabolic stress.

Experimental investigations have focused on cellular survival pathways and the regulation of tissue responses to damage.

Research involving erythropoietin-derived peptides has explored how tissue-protective signaling may differ from pathways responsible for red blood cell production.

These investigations contribute to the broader scientific understanding of cellular repair mechanisms and receptor-mediated stress responses.

Research Applications

FREQUENTLY ASKED QUESTIONS

What Is ARA-290 10mg?

ARA-290 10mg is a synthetic 11-amino-acid research peptide derived from a tissue-protective region of erythropoietin.

Also known as Cibinetide, it is investigated in research involving innate repair receptor signaling, inflammatory pathways, and peripheral nerve function.

What Is the Amino Acid Sequence of ARA-290?

The amino acid sequence is:

pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser

ARA-290 consists of 11 amino acid residues and contains an N-terminal pyroglutamate modification.

What Are the CAS Number and Molecular Weight of ARA-290?

ARA-290 has CAS number 1208243-50-8 and a molecular weight of approximately 1257.3 g/mol.

Its molecular formula is C₅₁H₈₄N₁₆O₂₁.

These specifications describe the parent Cibinetide compound.

How Should ARA-290 Be Stored?

ARA-290 should be stored according to the manufacturer’s recommended stability and temperature conditions.

The research material should remain protected from moisture, direct light, and unnecessary temperature fluctuations.

Specific storage requirements should be confirmed using technical documentation for the individual preparation.

What Research Areas Involve ARA-290?

ARA-290 has been investigated in experimental research involving innate repair receptor signaling, tissue-protective pathways, inflammation, peripheral nerve function, and cellular responses to injury.

What Is the Difference Between ARA-290 and Erythropoietin?

Erythropoietin is a naturally occurring glycoprotein hormone involved in the regulation of red blood cell production.

ARA-290 is a synthetic 11-amino-acid peptide developed from a tissue-protective region of erythropoietin.

Unlike conventional erythropoietin, ARA-290 was designed to investigate tissue-protective signaling without stimulating red blood cell production.

Is ARA-290 Approved for Human Use?

No. ARA-290, also known as Cibinetide, is not FDA-approved for human therapeutic use.

Peptide Lives supplies ARA-290 exclusively for laboratory research purposes.

SCIENTIFIC REFERENCES

1. Brines M. et al. (2008)

Nonerythropoietic, Tissue-Protective Peptides Derived from the Tertiary Structure of Erythropoietin.

Proceedings of the National Academy of Sciences, 105(31), 10925–10930.

This study investigated short erythropoietin-derived peptides and their tissue-protective activity in experimental models.

https://pubmed.ncbi.nlm.nih.gov/18676614/

2. Heij L. et al. (2012)

Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study.

Molecular Medicine, 18, 1430–1436.

This randomized pilot study investigated ARA-290 in 22 participants with sarcoidosis-associated small fiber neuropathy symptoms.

https://pubmed.ncbi.nlm.nih.gov/23168581/

3. Dahan A. et al. (2013)

ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density.

Molecular Medicine, 19, 334–345.

This clinical investigation examined neuropathic symptoms and corneal nerve fiber measurements.

https://pubmed.ncbi.nlm.nih.gov/24136731/

4. Brines M. et al. (2015)

ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes.

Molecular Medicine, 20, 658–666.

This phase 2 study investigated metabolic and neuropathy-related outcomes in individuals with type 2 diabetes.

https://pubmed.ncbi.nlm.nih.gov/25387363/

CERTIFICATE OF ANALYSIS (COA)

A Certificate of Analysis (COA) provides analytical information about a research compound, including its identity, purity, and other measured characteristics.

Depending on the analytical procedures performed, batch-specific documentation may include results from high-performance liquid chromatography (HPLC) and mass spectrometry (MS).

Researchers should review available testing documentation to verify compound identity and assess whether the research material meets their experimental requirements.

For information about available ARA-290 analytical documentation, contact:

Peptide Lives
Website: https://peptidelives.com